Nanjing Vcare Concludes a Successful CPHI China 2026 in Shanghai: Expanding Global Footprint and Empowering Worldwide Clients through Technological Innovation

2026-06-22

 

　　The 24th CPHI China 2026 was held at Shanghai New International Expo Centre from June 16 to 18. Nanjing Vcare PharmaTech Co.,Ltd. (Nanjing Vcare), together with its manufacturing subsidiary Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical), showcased its one-stop core CRO/CDMO technologies and comprehensive solutions at the exhibition. Backed by robust R&D innovation strengths and a well-defined global expansion strategy, the company earned widespread recognition from clients at home and abroad, marking a fruitful conclusion to its participation in the show.

　　As a highly influential international event in the biopharmaceutical sector, CPHI serves as a pivotal platform connecting the global pharmaceutical industry and facilitating cross-border collaboration. While consistently advancing its technological innovation capabilities, Nanjing Vcare has steadily rolled out its internationalization strategy, continuously boosting its brand influence and market penetration within the global pharmaceutical R&D services landscape.

　　At Booth W3E36, Nanjing Vcare exhibited its full-spectrum one-stop CRO/CDMO capabilities spanning early-stage drug research all the way to commercial manufacturing. The booth featured a lineup of high-end technical platforms including synthetic biology and green manufacturing, demonstrating its CDMO production and supply capacity for advanced pharmaceutical intermediates and specialty APIs, as well as end-to-end R&D services covering pharmaceutical CMC studies through clinical trials. Numerous domestic and international pharmaceutical enterprises stopped by for in-depth business discussions. This year’s CPHI Shanghai acted as a vital gateway for Nanjing Vcare to deepen global partnerships and expand overseas markets, further consolidating its service capacity across the worldwide pharmaceutical industrial chain.

　　Drawing on its formidable R&D and manufacturing strengths alongside an international quality management system, Nanjing Vcare will keep deepening core technological innovation and proactively pursuing global cooperation. The company aims to contribute to high-quality development of the global biopharmaceutical industry by delivering premium pharmaceutical R&D and manufacturing services to partners worldwide.

Prev

Ranking 7th! Nanjing Vcare Ranks among Top 20 Chinese R&D CRO Enterprises of 2026

Next

Powerful Empowerment! Nanjing Vcare Supports Parent Company Vcare PharmaTech in the Successful Approval and Launch of Its First Innovative Drug VELMARTO® (Eratrectinib)